These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24215309)

  • 41. Insulin therapy in type 2 diabetes.
    Campbell RK; White JR
    J Am Pharm Assoc (Wash); 2002; 42(4):602-11. PubMed ID: 12150359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin detemir: a long-acting insulin product.
    Jones MC; Patel M
    Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
    Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
    [No Abstract]   [Full Text] [Related]  

  • 44. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
    Owens DR; Matfin G; Monnier L
    Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin degludec for diabetes mellitus.
    Drug Ther Bull; 2013 Jul; 51(7):78-81. PubMed ID: 23842634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.
    Woo VC
    Clin Ther; 2017 Aug; 39(8S2):S12-S33. PubMed ID: 28187863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Insulin analogues: searching for a physiological replacement].
    Eyzaguirre F; Codner E
    Rev Med Chil; 2006 Feb; 134(2):239-50. PubMed ID: 16554934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH; Nattrass M; Pieber TR
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Insulin analogues: place of detemir (Levemir)].
    Dorchy H; Sternon J
    J Pharm Belg; 2006; 61(2):58-62. PubMed ID: 16866083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin lispro: a review of its use in the management of diabetes mellitus.
    Simpson D; McCormack PL; Keating GM; Lyseng-Williamson KA
    Drugs; 2007; 67(3):407-34. PubMed ID: 17335298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.
    Tibaldi JM
    Clin Ther; 2011 Nov; 33(11):1630-42. PubMed ID: 22030443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insulin analogues.
    Marks J
    Postgrad Med; 2002 Nov; 112(5 Suppl Designer):8-12. PubMed ID: 19667599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Editorial: diabetes and cancer - disease, drugs or deception?
    Vestergaard P
    Curr Drug Saf; 2013 Nov; 8(5):291. PubMed ID: 24215313
    [No Abstract]   [Full Text] [Related]  

  • 56. Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis.
    Wang L; Cai S; Teng Z; Zhao X; Chen X; Bai X
    Diagn Pathol; 2013 Oct; 8():180. PubMed ID: 24175949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.
    Werner H; Chantelau EA
    Diabetol Metab Syndr; 2011 Jun; 3(1):13. PubMed ID: 21714872
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations.
    Wild SH
    Diabetologia; 2011 Jul; 54(7):1589-92. PubMed ID: 21541783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diabetes mellitus and cancer risk: review of the epidemiological evidence.
    Shikata K; Ninomiya T; Kiyohara Y
    Cancer Sci; 2013 Jan; 104(1):9-14. PubMed ID: 23066889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pathway from diabetes and obesity to cancer, on the route to targeted therapy.
    Gallagher EJ; Fierz Y; Ferguson RD; LeRoith D
    Endocr Pract; 2010; 16(5):864-73. PubMed ID: 20841312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.